ArticleFrontiers in oncology2026
Comprehensive management of advanced lymphoepithelioma-like hepatocellular carcinoma with immune-related colitis: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Clinicopathological features and literature review of a case of lymphoepithelioma-like intrahepatic cholangiocarcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is an exceedingly rare hepatocellular carcinoma subtype characterized by prominent lymphocyte infiltration. LEL-HCC accounts for fewer than 1% of all HCCs, and most patients present with resectable disease at initial diagnosis. For unresectable LEL-HCC, chemoimmunotherapy is employed based on the experience of the attending physician. However, no recognized effective treatment for advanced LEL-HCC has been established. We present the case of a 68-year-old male with unresectable advanced LEL-HCC, which was ultimately diagnosed by laparoscopic partial hepatectomy biopsy after intraoperative needle biopsy proved inconclusive. We chose a therapeutic regimen consisting of micellar paclitaxel plus cisplatin chemotherapy in combination with immunotherapy for the patient. After 5 months of chemoimmunotherapy, the patient achieved partial response (PR) that was sustained for 8 months until the latest follow-up. Notably, grade 3 immune-related colitis occurred 6 months after commencing immune checkpoint inhibitor (ICI) treatment, which was effectively managed with corticosteroids and Infliximab. This report presents the first documented severe immune-related adverse event (irAE) in a patient with LEL-HCC, thereby informing the comprehensive management of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.